Genmab — August 2019
-
-
1.376

-
Også i følge dit link.

-
Jo, der burde være offentliggjort salgstal i dag baseret på optalte receptudskrivninger af Symphony Health. Men det er kun for betalende kunder. Når vi her på PI engang imellem får oplyst tallet er det kun fordi nogen har været så venlig at lade det sive. Vi kender heller ikke tallet for juni.
-
Key statistics for ALL https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html
-
Genmab A/S (Nasdaq: GMAB) announced today that preliminary data from the Phase I/II trial of enapotamab vedotin in advanced non-small cell lung cancer (NSCLC) has been accepted for oral presentation at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer (IASLC 2019 WCLC) taking place from September 7-10, 2019 in Barcelona, Spain
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind